CY1123410T1 - Συνθεσεις παρατεταμενης αποδεσμευσης με χρηση μη υδατικων φορεων - Google Patents
Συνθεσεις παρατεταμενης αποδεσμευσης με χρηση μη υδατικων φορεωνInfo
- Publication number
- CY1123410T1 CY1123410T1 CY20201100689T CY201100689T CY1123410T1 CY 1123410 T1 CY1123410 T1 CY 1123410T1 CY 20201100689 T CY20201100689 T CY 20201100689T CY 201100689 T CY201100689 T CY 201100689T CY 1123410 T1 CY1123410 T1 CY 1123410T1
- Authority
- CY
- Cyprus
- Prior art keywords
- active pharmaceutical
- extended release
- aqueous vehicles
- release compositions
- oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
Η αποκάλυψη παρέχει ενέσιμα σκευάσματα παρατεταμένης απελευθέρωσης ενός συστατικού τα οποία περιλαμβάνουν μικροσφαίρες οι οποίες περιέχουν δραστικά φαρμακευτικά συστατικά (π.χ. εξενατίδη) εντός των οποίων αιωρούνται οι μικροσφαίρες σε μη υδατικό φορέα. Ο μη υδατικός φορέας μπορεί να είναι έλαιο, κλασματοποιημένο έλαιο, τριγλυκερίδια. διγλυκερίδια. μονογλυκερίδια, διεστέρες λιπαρών οξέων προπυλενογλυκόλης και τα παρόμοια. Τα σκευάσματα παρέχουν διακριτά πλεονεκτήματα μακράς διάρκειας ζωής για τη σταθερότητα και την ισχύ του σκευάσματος και την παρατεταμένη αποδέσμευση του δραστικού φαρμακευτικού συστατικού, για τη μείωση της συχνότητας της δοσολογίας του φαρμάκου και για την αύξηση της συμμόρφωσης του ασθενούς.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9438108P | 2008-09-04 | 2008-09-04 | |
PCT/US2009/056058 WO2010028257A1 (en) | 2008-09-04 | 2009-09-04 | Sustained release formulations using non-aqueous carriers |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123410T1 true CY1123410T1 (el) | 2021-12-31 |
Family
ID=41797509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100689T CY1123410T1 (el) | 2008-09-04 | 2020-07-27 | Συνθεσεις παρατεταμενης αποδεσμευσης με χρηση μη υδατικων φορεων |
Country Status (24)
Country | Link |
---|---|
US (5) | US8895033B2 (el) |
EP (2) | EP3685837A1 (el) |
JP (2) | JP5744735B2 (el) |
KR (1) | KR101760953B1 (el) |
CN (2) | CN102164597B (el) |
AU (1) | AU2009289529B2 (el) |
BR (1) | BRPI0918904B8 (el) |
CA (1) | CA2734525C (el) |
CY (1) | CY1123410T1 (el) |
DK (1) | DK2341905T4 (el) |
EA (1) | EA020299B1 (el) |
ES (1) | ES2809178T3 (el) |
FI (1) | FI2341905T4 (el) |
HR (1) | HRP20201179T4 (el) |
HU (1) | HUE050125T2 (el) |
IL (1) | IL211231A (el) |
LT (1) | LT2341905T (el) |
MX (1) | MX352189B (el) |
NZ (1) | NZ604997A (el) |
PL (1) | PL2341905T5 (el) |
PT (1) | PT2341905T (el) |
SG (1) | SG10201703039SA (el) |
SI (1) | SI2341905T2 (el) |
WO (1) | WO2010028257A1 (el) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145164B (zh) * | 2010-12-16 | 2013-02-27 | 深圳市健元医药科技有限公司 | 一种更加稳定的iapp类似物注射剂 |
CN103826609A (zh) * | 2011-06-09 | 2014-05-28 | 安米林药品有限责任公司 | 凝胶组合物 |
EP2723359A4 (en) * | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | METHODS OF TREATING DIABETES WITH PROLONGED RELEASE FORMULATIONS OF GLP-1 PROCESS AGONISTS |
CN104840415B (zh) * | 2014-02-19 | 2019-03-15 | 香港浸会大学 | 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法 |
WO2015196174A1 (en) * | 2014-06-20 | 2015-12-23 | Greene Howard E | Infusion delivery devices and methods |
WO2016191395A1 (en) | 2015-05-22 | 2016-12-01 | The Bot Of The Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with exendin(9-39) |
US20180326080A1 (en) * | 2015-10-27 | 2018-11-15 | Purdue Research Foundation | Polymer-based therapeutics for inductive browning of fat |
WO2017152014A1 (en) | 2016-03-04 | 2017-09-08 | Eiger Biopharmaceuticals, Inc. | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives |
CA3021140A1 (en) | 2016-04-19 | 2017-10-26 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
CN110267648A (zh) | 2016-11-21 | 2019-09-20 | 艾格尔峰生物制药有限公司 | 毒蜥外泌肽(9-39)的缓冲制剂 |
MX2019007504A (es) | 2017-01-09 | 2020-07-29 | Asarina Pharma Ab | Suspensiones inyectables. |
CN108424460A (zh) * | 2017-02-13 | 2018-08-21 | 成都贝爱特生物科技有限公司 | GLP-1类似物和davalintide类似物的融合蛋白制备及其用途 |
KR101994456B1 (ko) * | 2017-03-15 | 2019-06-28 | 이건무 | 당 수액제 조성물 |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
JP2022519690A (ja) | 2019-02-05 | 2022-03-24 | リンディー バイオサイエンシーズ,インク. | 単離された細胞培養成分、及びそれを液状の細胞培養培地から単離する方法 |
KR102045721B1 (ko) * | 2019-03-27 | 2019-11-18 | 주식회사 씨트리 | 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구 |
WO2021053167A1 (de) * | 2019-09-19 | 2021-03-25 | Amw Gmbh | Extrudierte depotform mit kontrollierter wirkstofffreisetzung |
GB202004115D0 (en) * | 2020-03-20 | 2020-05-06 | Invex Therapeutics Ltd | Modified release formulations and dosage regimens |
BR102021001712A2 (pt) * | 2021-01-29 | 2022-08-16 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da diabetes mellitus tipo 2 e processo |
JP2024513509A (ja) * | 2021-04-08 | 2024-03-25 | ティオンラボ・セラピューティクス | 徐放性脂質前駆製剤 |
EP4326237A2 (en) * | 2021-04-23 | 2024-02-28 | Flow Pharma Inc. | Microsphere formulations comprising multiple non-identical peptides and methods for making the same |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61227520A (ja) * | 1985-04-02 | 1986-10-09 | Dai Ichi Seiyaku Co Ltd | マイクロスフエア |
US5439688A (en) | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
US5213810A (en) * | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
US5122377A (en) * | 1990-11-19 | 1992-06-16 | A.H. Robins, Company, Incorporated | Oral delivery system for veterinary drugs |
DE4122217C2 (de) | 1991-07-04 | 1997-02-13 | Merz & Co Gmbh & Co | Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6913767B1 (en) | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
US5718922A (en) | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US6245349B1 (en) * | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
DK0889722T3 (da) | 1996-03-28 | 2003-02-10 | Takeda Chemical Industries Ltd | Præparat med forsinket frigivelse og fremstilling deraf |
US7276251B2 (en) | 1997-04-01 | 2007-10-02 | Lg Life Sciences, Ltd., Inc. | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
ATE493998T1 (de) | 1996-08-08 | 2011-01-15 | Amylin Pharmaceuticals Inc | Pharmazeutische zusammensetzung mit einem exendin-4-peptid |
WO1998007412A1 (en) | 1996-08-21 | 1998-02-26 | Alkermes Controlled Therapeutics, Inc. | Controlled release microparticles with a hydrophobic material |
DK1629849T4 (en) | 1997-01-07 | 2017-12-04 | Amylin Pharmaceuticals Llc | Pharmaceutical compositions comprising exedins and agonists thereof |
TW577759B (en) | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
US7223725B1 (en) | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
CA2338031C (en) | 1998-07-17 | 2006-12-05 | Sankaram Bhima Mantripragada | Biodegradable compositions for the controlled release of encapsulated substances |
US6270700B1 (en) | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
US6872700B1 (en) | 1999-01-14 | 2005-03-29 | Amylin Pharmaceuticals, Inc. | Methods for glucagon suppression |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
DE10031744A1 (de) | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung |
US6967028B2 (en) * | 2000-07-31 | 2005-11-22 | Mainelab | Prolonged release microspheres for injectable administration |
US6479065B2 (en) | 2000-08-10 | 2002-11-12 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
EP1343478B1 (en) | 2000-12-21 | 2007-10-10 | Alrise Biosystems GmbH | Induced phase transition method for the production of microparticles containing hydrophilic active agents |
AUPR573001A0 (en) * | 2001-06-15 | 2001-07-12 | Glaxo Wellcome Australia Ltd | Lymphatic drug delivery system |
EP1406593B1 (en) | 2001-06-22 | 2010-08-25 | Johns Hopkins University School of Medicine | Biodegradable polymer compositions, compositions and uses related thereto |
US20050260259A1 (en) * | 2004-04-23 | 2005-11-24 | Bolotin Elijah M | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
DE60335608D1 (de) * | 2002-02-27 | 2011-02-17 | Pharmain Corp | Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung |
WO2004035754A2 (en) | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
EP1581181B1 (en) | 2002-11-06 | 2008-12-24 | ALZA Corporation | Controlled release depot formulations |
US20060099256A1 (en) | 2002-11-27 | 2006-05-11 | Price James C | Microspheres and related processes and pharmaceutical compositions |
IL155136A0 (en) * | 2003-02-10 | 2003-10-31 | Enzymotec Ltd | A composition for reducing blood cholesterol and triglycerides |
US20060148776A1 (en) * | 2003-03-13 | 2006-07-06 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
US20040224030A1 (en) * | 2003-05-06 | 2004-11-11 | Shastri Venkatram R. | Microsphere delivery systems |
US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
SI2409707T1 (sl) | 2004-04-15 | 2015-07-31 | Alkermes Pharma Ireland Limited | Naprava s podaljšanim sproščanjem na osnovi polimerov |
US7456254B2 (en) | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
US20050266087A1 (en) | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
CN2763883Y (zh) * | 2004-12-30 | 2006-03-08 | 鸿富锦精密工业(深圳)有限公司 | 电脑壳体前板锁固装置 |
US8299025B2 (en) | 2005-02-03 | 2012-10-30 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
PL1888031T3 (pl) * | 2005-06-06 | 2013-04-30 | Camurus Ab | Preparaty analogu glp-1 |
DK2347762T3 (da) † | 2005-08-19 | 2019-06-11 | Amylin Pharmaceuticals Llc | Exendin til behandling af diabetes og reduktion af kropsvægt |
WO2007022518A2 (en) | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
US20100210506A1 (en) * | 2005-10-20 | 2010-08-19 | Mdrna, Inc. | Intranasal administration of rapid acting insulin |
WO2007067964A2 (en) * | 2005-12-08 | 2007-06-14 | Nastech Pharmaceutical Company Inc. | Mucosal delivery of stabilized formulations of exendin |
BRPI0712559A2 (pt) | 2006-05-26 | 2012-11-20 | Amylin Pharmaceuticals Inc | composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva |
US20080145439A1 (en) * | 2006-07-31 | 2008-06-19 | Neurosystec Corporation | Nanoparticle drug formulations |
KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
CN101541313A (zh) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | 可注射的储库组合物及其制备方法 |
EP2011452B1 (fr) | 2007-07-06 | 2014-04-30 | S.B.I.R. Sprl | Préparation injectable pour la réalisation d'un implant musculaire |
ES2552646T3 (es) | 2008-05-21 | 2015-12-01 | Amylin Pharmaceuticals, Inc. | Exendinas para disminuir el colesterol y los triglicéridos |
-
2009
- 2009-09-04 JP JP2011526233A patent/JP5744735B2/ja active Active
- 2009-09-04 CN CN200980134725.7A patent/CN102164597B/zh active Active
- 2009-09-04 EP EP20163108.2A patent/EP3685837A1/en active Pending
- 2009-09-04 EP EP09812292.2A patent/EP2341905B2/en active Active
- 2009-09-04 EA EA201170413A patent/EA020299B1/ru not_active IP Right Cessation
- 2009-09-04 KR KR1020117007223A patent/KR101760953B1/ko active IP Right Grant
- 2009-09-04 US US13/060,225 patent/US8895033B2/en active Active
- 2009-09-04 NZ NZ604997A patent/NZ604997A/en unknown
- 2009-09-04 SI SI200932079T patent/SI2341905T2/sl unknown
- 2009-09-04 PT PT98122922T patent/PT2341905T/pt unknown
- 2009-09-04 SG SG10201703039SA patent/SG10201703039SA/en unknown
- 2009-09-04 BR BRPI0918904A patent/BRPI0918904B8/pt active IP Right Grant
- 2009-09-04 CN CN201410373411.5A patent/CN104248623B/zh active Active
- 2009-09-04 WO PCT/US2009/056058 patent/WO2010028257A1/en active Application Filing
- 2009-09-04 PL PL09812292.2T patent/PL2341905T5/pl unknown
- 2009-09-04 LT LTEP09812292.2T patent/LT2341905T/lt unknown
- 2009-09-04 FI FIEP09812292.2T patent/FI2341905T4/fi active
- 2009-09-04 CA CA2734525A patent/CA2734525C/en active Active
- 2009-09-04 MX MX2011002398A patent/MX352189B/es active IP Right Grant
- 2009-09-04 HU HUE09812292A patent/HUE050125T2/hu unknown
- 2009-09-04 DK DK09812292.2T patent/DK2341905T4/da active
- 2009-09-04 HR HRP20201179TT patent/HRP20201179T4/hr unknown
- 2009-09-04 ES ES09812292T patent/ES2809178T3/es active Active
- 2009-09-04 AU AU2009289529A patent/AU2009289529B2/en active Active
-
2011
- 2011-02-15 IL IL211231A patent/IL211231A/en active IP Right Grant
-
2014
- 2014-10-27 US US14/524,521 patent/US20150056285A1/en not_active Abandoned
-
2015
- 2015-02-05 JP JP2015021556A patent/JP6051243B2/ja active Active
-
2016
- 2016-08-11 US US15/234,021 patent/US20160346357A1/en not_active Abandoned
-
2018
- 2018-02-16 US US15/898,381 patent/US20180271946A1/en not_active Abandoned
-
2020
- 2020-05-13 US US15/931,123 patent/US20200405815A1/en not_active Abandoned
- 2020-07-27 CY CY20201100689T patent/CY1123410T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123410T1 (el) | Συνθεσεις παρατεταμενης αποδεσμευσης με χρηση μη υδατικων φορεων | |
UY33201A (es) | Compuestos de pirazol como antagonistas de crth2. | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
AR048963A1 (es) | Formulaciones de interferon de hidrogel de poloxamero | |
CY1108700T1 (el) | Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης | |
EA200501819A1 (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
HN2003000184A (es) | Preparaciones acidas de insulina con estabilidad mejorada | |
UY28906A1 (es) | Derivados de pirimidina que son antagonistas del receptor vitronectina | |
NO20053076D0 (no) | Farmasoytisk formulering med en uloselig aktiv forbindelse. | |
ECSP088666A (es) | Derivados de las benzamidas y heteroarenos | |
DK2058317T3 (da) | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens | |
IL182763A (en) | Indol-3-ylidene-hydrazino-biphenyl- carboxylic acid derivatives and pharmaceutical compositions comprising them for modulating thrombopoietin activity | |
CR11065A (es) | Administracion semanal de inhibidores de peptidasa de dipeptidilo | |
UY29701A1 (es) | Formulaciones líquidas para la administración controlada de derivados de bencisoxazol | |
WO2007014124A3 (en) | High drug load formulations and dosage forms | |
IL174655A0 (en) | Drug containing (2r)-2-propyloctanoic acid as the active ingredient | |
DOP2012000264A (es) | Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan | |
AR052233A1 (es) | Formulacion liofilizada, estabilizada, para derivados de la cefalosporina | |
IN2014DN08870A (el) | ||
ES2552754T1 (es) | Formulaciones de daptomicina y usos de la misma | |
CY1121655T1 (el) | Φαρμακευτικη συνθεση για αναστολεις της αποακετυλασης ιστονης | |
GT200300227A (es) | Formulaciones de liberacion prolongada en forma de suspension |